EUVIMEDEUVIMED entdecken
Crossref

Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study

Emily Stenke iD, Dahlal Alhassan, Molly Moclair, Sarah Cooper, Anna Dominika, Ciara Lang, Shoana Quinn iD, Annemarie Broderick iD, Emer Fitzpatrick iD, Billy Bourke iD, Lorraine Stallard iD, Séamus Hussey iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Emily Stenke und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Pediatric Gastroenterology, Children's Health Ireland at Crumlin, Dublin, Ireland. Hauptthemen laut MEDLINE: Infliximab, Drug Monitoring, Gastrointestinal Agents, Crohn Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Children's Medical and Research Foundation, Ireland, Children’s Medical and Research Foundation, Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proactive drug monitoring in our national cohort of children with inflammatory bowel disease suggested that 5 mg/kg dosing of infliximab (IFX) was associated with inadequate trough levels (TLs), thus we commenced empiric 10 mg/kg dosing in 2019.

Methods

This was a retrospective study of patients commenced on 5 or 10 mg/kg IFX between 2018 and 2020. The primary outcome was pre-fourth TL ≥5 µg/mL. Data source verification and analysis were undertaken retrospectively.

Results

During the study period, 122 patients were commenced on IFX and eligible for inclusion. Of these, 72% were male, 76% had Crohn’s disease (CD), 23% had ulcerative colitis; mean (standard deviation [SD]) age at diagnosis was 11.8 (2.7) years; 60 commenced 5 mg/kg. Baseline parameters were comparable between groups. Fewer patients in the 5 mg/kg than 10 mg/kg group had pre-fourth TLs ≥5 µg/mL (6/48 [12.5%] vs 28/50 [56%], P < .001; mean [SD] TL 3.5 [6.3] vs 10.0 [9.9], P < .001). The 5 mg/kg group was less likely to have target pre-third TLs (6% vs 80%, P < .001); more likely to have treatment escalation (78% vs 45%, P < .001), and less likely to de-escalate (10% vs 29% P = .008). Proactive therapeutic dose monitoring (TDM) was practiced throughout the study period and mean (SD) IFX exposure per kg/week was similar in both groups by 1 year (1.4 [0.43] vs 1.56 [0.56] mg/kg/week, P = .137), as were infliximab durability and clinical outcomes.

Conclusions

Our real-world data show that 5 mg/kg infliximab induction does not achieve target TLs in most children with CD. Higher-dose regimens should be considered, especially if proactive therapeutic drug monitoring is not available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabDrug MonitoringGastrointestinal AgentsCrohn DiseaseColitis, UlcerativeInflammatory Bowel DiseasesHumansRetrospective StudiesMaleFemaleChildAdolescentDose-Response Relationship, Drug

Stichwörter der Autor:innen

inflammatory bowel diseaseinfliximabpediatrictherapeutic dose monitoring

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • National Centre for Pediatric Gastroenterology, Children's Health Ireland at Crumlin, Dublin, Ireland.
  • The DOCHAS Study, Children's Health Ireland at Crumlin, Dublin, Ireland.
  • School of Medicine, University College Dublin, Dublin, Ireland.
  • Department of Pediatrics, Royal College of Surgeons of Ireland, Dublin, Ireland.

ORCID-Profile: Emily Stenke, Shoana Quinn, Annemarie Broderick, Emer Fitzpatrick, Billy Bourke, Lorraine Stallard, Séamus Hussey

Förderung

  • Children's Medical and Research Foundation, Ireland
  • Children’s Medical and Research Foundation, Ireland

Zitieren

APA

Stenke, E., Alhassan, D., Moclair, M., Cooper, S., Dominika, A., Lang, C., Quinn, S., Broderick, A., Fitzpatrick, E., Bourke, B., Stallard, L., & Hussey, S. (2025). Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf031

Vancouver

Stenke E, Alhassan D, Moclair M, Cooper S, Dominika A, Lang C, et al. Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf031

BibTeX
@article{Stenke2025,
  author = {Stenke, Emily and Alhassan, Dahlal and Moclair, Molly and Cooper, Sarah and Dominika, Anna and Lang, Ciara and Quinn, Shoana and Broderick, Annemarie and Fitzpatrick, Emer and Bourke, Billy and Stallard, Lorraine and Hussey, Séamus},
  title = {Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf031}
}
Kostenlos starten →